11.2 Antimicrobial Stewardship and Infection Prevention
Key Takeaways
- Antimicrobial stewardship programs (ASPs) in the ICU aim to optimize clinical outcomes while minimizing unintended consequences of antimicrobial use, such as toxicity, selection of pathogenic organisms, and the emergence of resistance.
- Critically ill patients exhibit altered pharmacokinetics (e.g., increased volume of distribution, augmented renal clearance) that necessitate optimized dosing strategies, such as prolonged infusions of beta-lactams.
- Rapid diagnostic testing (RDT) coupled with active stewardship intervention significantly decreases time to optimal antimicrobial therapy.
- De-escalation is a core stewardship principle in the ICU, involving the transition from broad-spectrum empiric therapy to targeted therapy based on culture results and clinical response.
The Intensive Care Unit accounts for a disproportionate amount of broad-spectrum antimicrobial use within hospitals. Patients in the ICU are at a high risk for healthcare-associated infections (HAIs) such as ventilator-associated pneumonia (VAP), central line-associated bloodstream infections (CLABSI), and catheter-associated urinary tract infections (CAUTI). Consequently, Antimicrobial Stewardship Programs (ASPs) are essential in the ICU to optimize therapy, improve patient outcomes, and combat the rising threat of multidrug-resistant organisms (MDROs).
Core Stewardship Strategies in the ICU
Effective ASPs in the critical care setting employ a variety of strategies to ensure appropriate antimicrobial use.
1. Prospective Audit and Feedback (PAF)
PAF involves an infectious diseases physician or stewardship pharmacist reviewing antimicrobial orders and providing direct, real-time feedback to the primary ICU team. This is often performed after 48-72 hours of therapy when culture data becomes available, prompting discussions on de-escalation, duration of therapy, or intravenous to oral (IV to PO) conversion.
2. Preauthorization
This strategy requires approval from an ASP member before certain restricted, broad-spectrum, or high-cost antimicrobials (e.g., ceftazidime-avibactam, meropenem-vaborbactam) can be dispensed. While effective at controlling the use of specific agents, it can be resource-intensive and potentially delay care if not implemented efficiently.
3. De-escalation
De-escalation is a fundamental concept in ICU stewardship. Critically ill patients with suspected sepsis often require prompt, broad-spectrum empiric therapy. However, once culture results and susceptibilities are available, therapy must be narrowed to target the specific pathogen. If cultures are negative and the patient has clinically improved, discontinuing antimicrobials entirely should be considered.
Pharmacokinetic and Pharmacodynamic (PK/PD) Optimization
Critically ill patients undergo profound physiologic changes that significantly alter drug PK/PD parameters. The "one size fits all" dosing approach is inappropriate in the ICU.
| PK Parameter | ICU Alteration | Clinical Implication |
|---|---|---|
| Volume of Distribution (Vd) | Increased due to fluid resuscitation, capillary leak, and hypoalbuminemia. | Requires higher initial loading doses for hydrophilic drugs (e.g., beta-lactams, aminoglycosides, vancomycin) to achieve therapeutic target concentrations rapidly. |
| Clearance (Cl) | May be increased (Augmented Renal Clearance) or decreased (Acute Kidney Injury). | Requires vigilant monitoring and dynamic dose adjustments. Augmented renal clearance (ARC) may necessitate higher daily maintenance doses or more frequent administration. |
Beta-Lactam Dosing Strategies
Beta-lactams (penicillins, cephalosporins, carbapenems) exhibit time-dependent bactericidal activity. Their efficacy is best predicted by the percentage of the dosing interval that the free drug concentration remains above the minimum inhibitory concentration (MIC) of the pathogen (%fT > MIC).
To optimize this PD target in the ICU, especially against less susceptible pathogens like Pseudomonas aeruginosa, extended or continuous infusions are often utilized. By infusing the drug over 3-4 hours (extended) or 24 hours (continuous) rather than the traditional 30 minutes, the time above the MIC is significantly prolonged, improving clinical cure rates.
Rapid Diagnostic Testing (RDT)
Traditional microbiological cultures can take 48-72 hours to yield species identification and susceptibility data. Rapid diagnostic tests, such as multiplex polymerase chain reaction (PCR), matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, and microarray technologies, can identify pathogens and genetic resistance markers within hours.
However, RDT alone is insufficient. Studies have consistently shown that RDT must be coupled with active antimicrobial stewardship intervention (e.g., a pharmacist calling the team with the results and a recommendation) to realize benefits such as decreased time to optimal therapy and reduced length of stay.
Infection Prevention Bundles
Pharmacists play a key role in supporting infection prevention efforts. This includes ensuring compliance with bundles for preventing HAIs:
- VAP Bundles: Elevation of the head of the bed, daily "sedation vacations" and assessment of readiness to extubate, peptic ulcer disease (PUD) prophylaxis, and deep vein thrombosis (DVT) prophylaxis.
- CLABSI Bundles: Maximum sterile barrier precautions during insertion, chlorhexidine skin antisepsis, optimal catheter site selection, and daily review of line necessity with prompt removal of unnecessary lines.
Clinical Scenario
A 55-year-old female is admitted with septic shock secondary to pneumonia. She receives fluid resuscitation and is started on empiric piperacillin-tazobactam and vancomycin. At 48 hours, she is hemodynamically stable and off vasopressors. Respiratory cultures grow Streptococcus pneumoniae sensitive to ceftriaxone. Blood cultures are negative.
Discussion: The stewardship pharmacist rounds with the ICU team and recommends de-escalation. The piperacillin-tazobactam and vancomycin should be discontinued, and therapy should be narrowed to ceftriaxone. Additionally, based on her clinical improvement, the pharmacist suggests defining a total treatment duration of 5-7 days rather than a prolonged 14-day course.
Which of the following pharmacokinetic changes is most likely to occur in a patient with severe sepsis undergoing massive fluid resuscitation, and what is the corresponding dosing adjustment for a hydrophilic antimicrobial like a beta-lactam?
A hospital implements a new Rapid Diagnostic Testing (RDT) panel for blood cultures. To maximize the clinical impact of this technology and decrease the time to optimal antimicrobial therapy, which strategy is most critical?
To optimize the pharmacodynamics of beta-lactam antibiotics against highly resistant Gram-negative organisms in the ICU, which of the following administration strategies is most appropriate?